Parkinson's disease (PD) is a progressive neurological disorder whose pathophysiology involves dopaminergic depletion and accumulating effects of alpha-synuclein species.1The therapeutic approaches are aimed at dopamine replacement, and they focus on restoring dopaminergic activity to control motor symptoms.2Although these treatments can initially relieve symptoms, complex fluctuations and dyskinesias can develop over time, affecting the quality of life (QoL) and mobility of the patients. The gene discussed is SNCA; the disease is Parkinson disease.